Symtuza

Janssen Products LP🇺🇸 United States

FDA Page

Effective Date: Apr 17, 2026
Approval ID: 85a17d00-6b7c-41ea-a6b3-5ad924820dab
Products: 1 registered
Version: 23

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use SYMTUZA safely and effectively. See full prescribing information for SYMTUZA. SYMTUZA (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) tablets, for oral use Initial U.S. Approval: 2018

Quick Stats

Total Products1

Labelers2

Label Sections21

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.